The ongoing prospective, single-arm, observational, phase 4 ETNA-AF Europe study is collecting real-world data about the safety and, secondarily, the effectiveness and therapeutic adherence of newly prescribed edoxaban for non-valvular atrial fibrillation in Europe.
One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe
Ameri P.;
2020-01-01
Abstract
The ongoing prospective, single-arm, observational, phase 4 ETNA-AF Europe study is collecting real-world data about the safety and, secondarily, the effectiveness and therapeutic adherence of newly prescribed edoxaban for non-valvular atrial fibrillation in Europe.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ETNA-AF_first year FUP_GIC 2020.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
107.23 kB
Formato
Adobe PDF
|
107.23 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
